Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride

References

• Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y et al. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55:2256–2264.
   PubMed Web of Science ®Google Scholar
• Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H et al. (2008). Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes, 57:1414–1418.
   PubMed Web of Science ®Google Scholar
• Letasiová S, Jantová S, Cipák L, Múcková M. (2006). Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett, 239:254–262.
   PubMed Web of Science ®Google Scholar
• Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. (2008). Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res, 68:5370–5379.
   PubMed Web of Science ®Google Scholar
• Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY. (2007). Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res, 56:193–201.
   PubMed Web of Science ®Google Scholar
• Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med, 10:1344–1351.
   PubMed Web of Science ®Google Scholar
• Tan W, Li Y, Chen M, Wang Y. (2011). Berberine hydrochloride: anticancer activity and nanoparticulate delivery system. Int J Nanomedicine, 6:1773–1777.
   PubMedGoogle Scholar
• Asada H, Douen T, Waki M, Adachi S, Fujita T, Yamamoto A et al. (1995). Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J Pharm Sci, 84:682–687.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. (2000). Intestinal permeation enhancers. J Pharm Sci, 89:429–442.
   PubMed Web of Science ®Google Scholar
• Sakuma S, Hayashi M, Akashi M. (2001). Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Deliv Rev, 47:21–37.
   PubMed Web of Science ®Google Scholar
• Janes KA, Calvo P, Alonso MJ. (2001). Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliv Rev, 47:83–97.
   PubMed Web of Science ®Google Scholar
• Wang J, Chow D, Heiati H, Shen WC. (2003). Reversible lipidization for the oral delivery of salmon calcitonin. J Control Release, 88:369–380.
   PubMed Web of Science ®Google Scholar
• Dong Z, Hamid KA, Gao Y, Lin Y, Katsumi H, Sakane T et al. (2011). Polyamidoamine dendrimers can improve the pulmonary absorption of insulin and calcitonin in rats. J Pharm Sci, 100:1866–1878.
   PubMed Web of Science ®Google Scholar
• Yu C, Gu P, Zhang W, Qi N, Cai C, He H et al. (2011). Preparation and evaluation of zolmitriptan submicron emulsion for rapid and effective nasal absorption in beagle dogs. Drug Dev Ind Pharm, 37:1509–1516.
   PubMed Web of Science ®Google Scholar
• Ghosh PK, Murthy RS. (2006). Microemulsions: a potential drug delivery system. Curr Drug Deliv, 3:167–180.
   PubMedGoogle Scholar
• Balakrishnan P, Lee BJ, Oh DH, Kim JO, Lee YI, Kim DD et al. (2009). Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. Int J Pharm, 374:66–72.
   PubMed Web of Science ®Google Scholar
• Qi X, Wang L, Zhu J. (2011). Water-in-oil-in-water double emulsions: an excellent delivery system for improving the oral bioavailability of pidotimod in rats. J Pharm Sci, 100:2203–2211.
   PubMed Web of Science ®Google Scholar
• Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JP. (2009). Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm, 35:603–611.
   PubMed Web of Science ®Google Scholar
• Wu X, Xu J, Huang X, Wen C. (2011). Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm, 37:15–23.
   PubMed Web of Science ®Google Scholar
• Wu W, Wang Y, Que L. (2006). Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm, 63:288–294.
   PubMed Web of Science ®Google Scholar
• Zhang P, Liu Y, Feng N, Xu J. (2008). Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm, 355:269–276.
   PubMed Web of Science ®Google Scholar
• Constantinides PP. (1995). Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res, 12:1561–1572.
   PubMed Web of Science ®Google Scholar
• Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. (2007). Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm, 66:227–243.
   PubMed Web of Science ®Google Scholar
• Pouton CW. (2000). Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci, 11 Suppl 2:S93–S98.
   PubMed Web of Science ®Google Scholar
• Humberstone AJ, Charman WN. (1997). Lipid vehicles for the drug delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 25:103–128.
   Web of Science ®Google Scholar
• Grove M, Müllertz A, Nielsen JL, Pedersen GP. (2006). Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. Eur J Pharm Sci, 28:233–242.
   PubMed Web of Science ®Google Scholar
• O’Driscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15:405–415.
   PubMed Web of Science ®Google Scholar
• Swenson ES, Mehta SC, Radebaugh GW. (1994). Targeting lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator via a formulation approach. Int J Pharm, 108:85–93.
   Web of Science ®Google Scholar
• Klous MG, Nuijen B, Van den Brink W, Van Ree JM, Beijnen JH. (2004). Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach. Int J Pharm, 285:65–75.
   PubMed Web of Science ®Google Scholar
• Kommuru TR, Gurley B, Khan MA, Reddy IK. (2001). Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm, 212:233–246.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Ray S, Ghosal SK, Bhadra R, Moulik SP. (2004). Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull, 27:1993–1999.
   PubMed Web of Science ®Google Scholar
• Venkatesh G, Majid MI, Mansor SM, Nair NK, Croft SL, Navaratnam V. (2010). In vitro and in vivo evaluation of self-microemulsifying drug delivery system of buparvaquone. Drug Dev Ind Pharm, 36:735–745.
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun J, Zhang T, Liu H, He F, He Z. (2011). Enhanced oral bioavailability of tacrolimus in rats by self-microemulsifying drug delivery systems. Drug Dev Ind Pharm, 37:1225–1230.
   PubMed Web of Science ®Google Scholar
• Patel AR, Vavia PR. (2007). Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J, 9:E344–E352.
   PubMed Web of Science ®Google Scholar
• Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H et al. (2009). Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm, 371:148–155.
   PubMed Web of Science ®Google Scholar